B
Brigitte Dréno
Researcher at University of Nantes
Publications - 727
Citations - 45257
Brigitte Dréno is an academic researcher from University of Nantes. The author has contributed to research in topics: Acne & Melanoma. The author has an hindex of 76, co-authored 672 publications receiving 38756 citations. Previous affiliations of Brigitte Dréno include Centre national de la recherche scientifique & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Journal ArticleDOI
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty,Caroline Robert,Peter Hersey,Paul C. Nathan,Claus Garbe,Mohammed M. Milhem,Lev V. Demidov,Jessica C. Hassel,Piotr Rutkowski,Peter Mohr,Reinhard Dummer,Uwe Trefzer,James Larkin,Jochen Utikal,Brigitte Dréno,Marta Nyakas,Mark R. Middleton,Juergen C. Becker,Michelle Casey,Laurie Sherman,Frank S. Wu,Daniele Ouellet,Anne-Marie Martin,Kiran Patel,Dirk Schadendorf +24 more
TL;DR: Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Journal ArticleDOI
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin,Paolo A. Ascierto,Brigitte Dréno,Victoria Atkinson,Gabriella Liszkay,Michele Maio,Mario Mandalà,Lev V. Demidov,Daniil Stroyakovskiy,Luc Thomas,Luis de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Mika A. Sovak,Ilsung Chang,Nicholas Choong,Stephen P. Hack,Grant A. McArthur,Antoni Ribas +18 more
TL;DR: The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.
Journal ArticleDOI
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Mark R. Middleton,Jean-Jacques Grob,Neil K. Aaronson,G. Fierlbeck,Wolfgang Tilgen,S. Seiter,M. E. Gore,Steinar Aamdal,Jonathan Cebon,Alan S. Coates,Brigitte Dréno,M. Henz,Dirk Schadendorf,Alexander Kapp,Jürgen Weiss,U. Fraass,P. Statkevich,Martin J. Muller,Nick Thatcher +18 more
TL;DR: Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma.